New drug trial targets skin and scalp woes in down syndrome
NCT ID NCT07242638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily pill called abrocitinib for people with Down syndrome who have eczema or a type of hair loss. About 56 participants will take the drug for up to 60 weeks to see if it safely controls their skin or scalp condition. The goal is to manage symptoms, not cure the disease, and participants may need to stay on the medication long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••